Abstract:The high incidence of complex diseases has become a worldwide threat to human health. Multiple targets and pathways are perturbed during the pathological process of complex diseases. Systematic investigation of complex relationship between drugs and diseases is necessary for new association discovery and drug repurposing. For this purpose, three causal networks were constructed herein for cardiovascular diseases, diabetes mellitus, and neoplasms, respectively. A causal inference-probabilistic matrix factorization (CI-PMF) approach was proposed to predict and classify drug-disease associations, and further used for drug-repositioning predictions. First, multilevel systematic relations between drugs and diseases were integrated from heterogeneous databases to construct causal networks connecting drug-target-pathway-gene-disease. Then, the association scores between drugs and diseases were assessed by evaluating a drug's effects on multiple targets and pathways. Furthermore, PMF models were learned based on known interactions, and associations were then classified into three types by trained models. Finally, therapeutic associations were predicted based upon the ranking of association scores and predicted association types. In terms of drug-disease association prediction, modified causal inference included in CI-PMF outperformed existing causal inference with a higher AUC (area under receiver operating characteristic curve) score and greater precision. Moreover, CI-PMF performed better than single modified causal inference in predicting therapeutic drug-disease associations. In the top 30% of predicted associations, 58.6% (136/232), 50.8% (31/61), and 39.8% (140/352) hit known therapeutic associations, while precisions obtained by the latter were only 10.2% (231/2264), 8.8% (36/411), and 9.7% (189/1948). Clinical verifications were further conducted for the top 100 newly predicted therapeutic associations. As a result, 21, 12, and 32 associations have been studied and many treatment effects of drugs on diseases were investigated for cardiovascular diseases, diabetes mellitus, and neoplasms, respectively. Related chains in causal networks were extracted for these 65 clinical-verified associations, and we further illustrated the therapeutic role of etodolac in breast cancer by inferred chains. Overall, CI-PMF is a useful approach for associating drugs with complex diseases and provides potential values for drug repositioning.

Shared etiology of Mendelian and complex disease supports drug discovery

Shared genetics between breast cancer and its predisposing diseases identify novel breast cancer treatment candidates

Strategies to Identify Genes for Complex Diseases.

Facilitating Anti-Cancer Combinatorial Drug Discovery by Targeting Epistatic Disease Genes.

Shared genetics between breast cancer and predisposing diseases identifies novel breast cancer treatment candidates

Strategies and Methods to Identify Genes for Complex Diseases

Inferring Drug-Disease Associations Based on Known Protein Complexes

A Co-Module Approach for Elucidating Drug-Disease Associations and Revealing Their Molecular Basis.

Systems Chemical Genetics-Based Drug Discovery: Prioritizing Agents Targeting Multiple/Reliable Disease-Associated Genes as Drug Candidates

Drug-Disease Association and Drug-Repositioning Predictions in Complex Diseases Using Causal Inference-Probabilistic Matrix Factorization

Beyond disease susceptibility-Leveraging genome-wide association studies for new insights into complex disease biology

Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval

How do stochastic processes and genetic threshold effects explain incomplete penetrance and inform causal disease mechanisms?

Genetic drug target validation using Mendelian randomisation

Leveraging pleiotropy for the improved treatment of psychiatric disorders

Robust use of phenotypic heterogeneity at drug target genes for mechanistic insights: Application of cis‐multivariable Mendelian randomization to GLP1R gene region

Pharmacogenomics of Rare and Monogenic Disorders

Identification of rare disease genes as drivers of common diseases through tissue-specific gene regulatory networks

Common pitfalls in drug target Mendelian randomization and how to avoid them

Investigating the common genetic architecture and causality of metabolic disorders with neurodegenerative diseases

Prioritising genetic findings for drug target identification and validation